ATC code None CAS Number 134234-12-1 IUPHAR/BPS 4163 Molar mass 327.416 g/mol ChEMBL ID 17350 IUPHAR/BP 4163 | Synonyms CP-101,606 PubChem CID 219101 UNII UTC046R5HM Pubchem 219101 ChemSpider ID 189919 | |
 | ||
Traxoprodil (CP-101,606) is a drug developed by Pfizer which acts as an NMDA antagonist, selective for the NR2B subunit. It has neuroprotective, analgesic, and anti-Parkinsonian effects in animal studies. Traxoprodil has been researched in humans as a potential treatment to lessen the damage to the brain after stroke, but results from clinical trials showed only modest benefit. The drug was found to cause EKG abnormalities (QT prolongation) and its clinical development was stopped. More recent animal studies have suggested traxoprodil may exhibit rapid-acting antidepressant effects similar to those of ketamine, although there is some evidence for similar psychoactive side effects and abuse potential at higher doses, which might limit clinical acceptance of traxoprodil for this application.